In this article, we will discuss Rucaparib (Dosage Overview). So, let’s get started.
Maintenance Treatment of Recurrent Ovarian Cancer
Rucaparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or
primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Treatment of BRCA-mutated Ovarian Cancer After 2 or More Chemotherapies
Rucaparib is indicated for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for rucaparib.
The recommended dose of rucaparib is 600 mg (two 300 mg tablets) taken orally twice daily with or without food.
Continue treatment until disease progression or unacceptable toxicity.
If a patient misses a dose of rucaparib, instruct the patient to take the next dose at its scheduled time. Vomited doses should
not be replaced.